Outcomes in COVID-19 zavegepant studies

0 0.5 1 1.5+ All studies -168% 1 43 Improvement, Studies, Patients Relative Risk Mortality -168% 1 43 ICU admission -25% 1 43 RCTs -168% 1 43 Late -168% 1 43 Zavegepant for COVID-19 c19early.org November 2025 Favorszavegepant Favorscontrol
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ BHV-3500 Amali (DB RCT) -168% 2.68 [0.34-20.9] death 5/28 1/15 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.35 Late treatment -168% 2.68 [0.34-20.9] 5/28 1/15 168% higher risk All studies -168% 2.68 [0.34-20.9] 5/28 1/15 168% higher risk 1 zavegepant COVID-19 study c19early.org November 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.35 Effect extraction pre-specified(most serious outcome) Favors zavegepant Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ BHV-3500 Amali (DB RCT) -168% 2.68 [0.34-20.9] 5/28 1/15 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.35 Late treatment -168% 2.68 [0.34-20.9] 5/28 1/15 168% higher risk All studies -168% 2.68 [0.34-20.9] 5/28 1/15 168% higher risk 1 zavegepant COVID-19 mortality result c19early.org November 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.35 Favors zavegepant Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ BHV-3500 Amali (DB RCT) -25% 1.25 [0.38-4.14] 7/28 3/15 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.73 Late treatment -25% 1.25 [0.38-4.14] 7/28 3/15 25% higher risk All studies -25% 1.25 [0.38-4.14] 7/28 3/15 25% higher risk 1 zavegepant COVID-19 ICU result c19early.org November 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.73 Favors zavegepant Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ BHV-3500 Amali (DB RCT) -11% 1.11 [0.84-1.47] no recov. 20 (n) 11 (n) Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.47 Late treatment -11% 1.11 [0.84-1.47] 20 (n) 11 (n) 11% higher risk All studies -11% 1.11 [0.84-1.47] 20 (n) 11 (n) 11% higher risk 1 zavegepant COVID-19 recovery result c19early.org November 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.47 Favors zavegepant Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ BHV-3500 Amali (DB RCT) -168% 2.68 [0.34-20.9] death 5/28 1/15 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.35 Late treatment -168% 2.68 [0.34-20.9] 5/28 1/15 168% higher risk All studies -168% 2.68 [0.34-20.9] 5/28 1/15 168% higher risk 1 zavegepant COVID-19 Randomized Controlled Trial c19early.org November 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.35 Effect extraction pre-specified(most serious outcome) Favors zavegepant Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ BHV-3500 Amali (DB RCT) -168% 2.68 [0.34-20.9] 5/28 1/15 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.35 Late treatment -168% 2.68 [0.34-20.9] 5/28 1/15 168% higher risk All studies -168% 2.68 [0.34-20.9] 5/28 1/15 168% higher risk 1 zavegepant COVID-19 RCT mortality result c19early.org November 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.35 Favors zavegepant Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ BHV-3500 Amali (DB RCT) -168% 2.68 [0.34-20.9] death 5/28 1/15 Improvement, RR [CI] Treatment Control BHV-3500 Amali (DB RCT) -25% 1.25 [0.38-4.14] ICU 7/28 3/15 BHV-3500 Amali (DB RCT) -11% 1.11 [0.84-1.47] no recov. 20 (n) 11 (n) Zavegepant COVID-19 outcomes c19early.org November 2025 Favors zavegepant Favors control